ALS Association tool aims to help patients navigate insurance issues

Voyager Therapeutics reassesses SOD1-ALS gene therapy program

Voyager Therapeutics will reassess its gene therapy program for amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene after its original candidate, VY9323, was found to have toxic effects in nonhuman primate studies. The company believes the problem lies with the therapy’s payload and not the viral carrier…